Impact of Multiplex Polymerase Chain Reaction Test in Patients With Meningitis or Encephalitis

Daisuke Kitagawa1,2, Taito Kitano3, Yuto Uchihara4

  • 1Department of Laboratory Medicine, Nara Prefecture General Medical Center, Nara, Japan.

PubMed
Abstract

Insights

The FilmArray meningitis/encephalitis (FAME) panel significantly reduced antiviral treatment duration in Japanese hospitals. However, length of stay and antibacterial use remained unchanged, necessitating further evaluation of FAME

Area of Science:

  • Clinical microbiology
  • Infectious diseases
  • Hospital epidemiology

Background:

  • The FilmArray meningitis/encephalitis (FAME) panel is a multiplex nucleic acid test used for diagnosing central nervous system infections.
  • Evaluating the clinical and economic impact of diagnostic panels like FAME is crucial for optimizing patient care and resource allocation in hospitals.

Purpose of the Study:

  • To assess the impact of implementing the FAME panel on length of stay (LOS) and duration of antimicrobial treatment in pediatric and adult patients.
  • To analyze changes in diagnostic practices and pathogen identification rates following FAME panel adoption.

Main Methods:

  • A retrospective cohort study was conducted in a Japanese community hospital from January 2016 to December 2022.
  • Patients with cerebrospinal fluid (CSF) samples were included, with specific criteria for infants (<2 months) and those with elevated white blood cell counts (≥5/μL).
  • Multivariate Poisson regression analyses were used to compare days of therapy (DOT) and LOS between the pre-FAME and FAME implementation periods.

Main Results:

  • Pathogen-specific polymerase chain reaction (PCR) use increased significantly from 3.7% to 57.5% (P < .001) after FAME implementation.
  • The overall pathogen identification rate rose from 0.4% to 18.7% (P < .001).
  • While antibacterial DOT showed no significant difference (aRR, 1.06; P = .063), antiviral DOT was significantly reduced in the FAME period (aRR, 0.80; P < .001).

Conclusions:

  • The FAME panel led to a significant decrease in antiviral treatment duration but did not impact LOS or antibacterial use.
  • External factors, such as the COVID-19 pandemic, may have influenced meningitis and encephalitis epidemiology, confounding the observed results.
  • Continuous monitoring of FAME's clinical impact and the epidemiology of meningitis/encephalitis is recommended to refine its appropriate use.

Related Concept Videos

Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...